A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008398/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the
safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2
dose of MLN4924 as well as evaluate antitumor activity in patients with metastatic melanoma.
提供机构：
Vivli
创建时间：
2022-08-29
